HiJoJo Partners has successfully completed distribution of its second fund. The unique investment opportunity which closed in December was in the exciting genetics and research platform, 23andMe.
The direct-to-cap table transaction puts HiJoJo Partners and its investors alongside global leaders in VC and PE such as Sequoia and Fidelity as well as big pharma (Glaxo, Johnson & Johnson, etc). HiJoJo and its investors are excited to be part of this opportunity in cutting-edge and transformative technology.
23andMe is an operator of a consumer genetics and research platform designed to help people access, understand and benefit from the human genome. The company’s consumer genetics and research platform provide web-based interactive tools for individuals to learn and explore their own genetic information through DNA analysis technologies, enabling users to gain deeper insights into personal ancestry, genealogy and inherited traits. (Source: PitchBook Data Inc.)
HiJoJo Partners has successfully completed distribution of its second fund. The unique investment opportunity which closed in December was in the exciting genetics and research platform, 23andMe.
The direct-to-cap table transaction puts HiJoJo Partners and its investors alongside global leaders in VC and PE such as Sequoia and Fidelity as well as big pharma (Glaxo, Johnson & Johnson, etc). HiJoJo and its investors are excited to be part of this opportunity in cutting-edge and transformative technology.
23andMe is an operator of a consumer genetics and research platform designed to help people access, understand and benefit from the human genome. The company’s consumer genetics and research platform provide web-based interactive tools for individuals to learn and explore their own genetic information through DNA analysis technologies, enabling users to gain deeper insights into personal ancestry, genealogy and inherited traits. (Source: PitchBook Data Inc.)
